Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 39Terminated 15Unknown 10Recruiting 10Not yet recruiting 3Active not recruiting 2Withdrawn 1No longer available 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3Carcinoma, Neuroendocrine 1CRC 1

Interventions

Bevacizumab 38Capecitabine 17Oxaliplatin 16Irinotecan 15Leucovorin 12HMPL-013 12Fluorouracil 11Cetuximab 10trifluridine tipiracil drug combination 7irinotecan sucrosofate 6tipiracil 5Trifluridine 5Folfox protocol 5Drug Therapy 5tislelizumab 4Standard of Care 4Specimen Handling 4Mitomycin 4trametinib 3toripalimab 3pembrolizumab 3Magnetic Resonance Spectroscopy 3Injections 3IFL protocol 3Colonoscopy 3Blood Specimen Collection 3sotorasib 2sintilimab 2regorafenib 2dehydroftorafur 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Colorectal Neoplasms × IFL protocol × Clear all
NCT07359456 2026-05-19

COLIBRI-GI

UNICANCER

Phase 2 Not yet recruiting
130 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Not yet recruiting
100 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07021950 2025-06-15

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
130 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡